Temperature response to acetaminophen and risk of occult bacteremia: A case-control study: Mazur LJ, Jones TM, Kozinetz CA J Pediatr 6:888–891 Dec 1989

✍ Scribed by Jeff Bernstein

• Book ID: 104311179
• Publisher: Elsevier Science
• Year: 1990
• Tongue: English
• Weight: 233 KB
• Volume: 19
• Category: Article
• ISSN: 1097-6760
• DOI: 10.1016/s0196-0644(05)82496-5

✦ Synopsis

the use of a symptoms questionnaire, and either dexamethasone (4 mg every six hours) or placebo was given for the duration of exposure after AMS was diagnosed. Four weeks after the first exposure, the protocol was repeated and the subjects were given the opposite treatment. Five of the six subjects became ill during both periods of decompression, and therefore could be given both dexamethasone and placebo. All subjects had rapid improvement of their symptoms after receiving dexamethasone, and four of five were clinically well within 12 hours. Dexamethasone was shown to reduce the symptoms of AMS by 63% (P < .05), whereas placebo reduced symptoms by only 23% (not significant). Dexamethasone had no effect on such parameters as oxygen saturation, sleep apnea, urinary catecholamine levels, fluid shifts, perfusion scans, hematocrit, and psychomotor tests. Dexamethasone did produce mild hyperglycemia in all subjects. The authors conclude that dexamethasone reduces the symptoms of AMS but does not improve physiologic abnormalities related to high-altitude exposure. They therefore recommend the usage of dexamethasone only when descent is impossible.